Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Unknown 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

Carboplatin 8Paclitaxel 7Taxes 6Cisplatin 6pembrolizumab 5Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Platinum 4Fluorouracil 4Capecitabine 41,2-diaminocyclohexaneplatinum II citrate 4Radiotherapy, Conformal 3Metformin 3Etoposide 3Doxorubicin 3Cyclophosphamide 3Brachytherapy 3folfirinox 2aumolertinib 2Radiotherapy 2Proton Therapy 2Prednisone 2Oxaliplatin 2Nivolumab 2Magnetic Resonance Spectroscopy 2Leucovorin 2Ifosfamide 2Gemcitabine 2Folfox protocol 2Drug Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Has results × aumolertinib × Clear all
NCT02981108 2023-01-23

A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1/2 Unknown
364 enrolled 29 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03849768 2023-01-20

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 3 Unknown
429 enrolled 18 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡